GILD

Gilead Sciences, Inc.

  • sector: Healthcare
  • in 2 Arithmos indices

Indices that include GILD 2/2

sort
weight≥ 0.0%
alongside
  1. #1

    Recession-Resilient US Defensive 20 — Equal-Weighted

    GILD · 5.00%JNJABBVUNHMRK+15 more

    Biopharmaceutical leader in HIV, hepatitis, and oncology; 79% gross margin and 41% ROE with moderate P/E (19.7) indicate consistent FCF profile. Equal-weighted per user specification.

    CAGR
    8.6%
    Sharpe
    0.57
    max DD
    -26.3%
  2. #2

    Recession-Resilient US Defensive 20 — Equal-Weighted

    GILD · 5.00%PGKOPEPCL+15 more

    Biopharmaceutical company with $165B market cap and 79% gross margin. Equal-weighted at 5%; HIV and oncology franchises provide predictable cash generation.

    CAGR
    2.5%
    Sharpe
    0.20
    max DD
    -14.2%

Build your own index that includes GILD.

Write a plain-English prompt, get transparent rules and a 10-year backtest.

start a prompt →

Performance figures are simulated backtests, not live returns. Past performance does not predict future results. Arithmos is a research and data tool, not investment advice.

/home·/markets·/feed·/leaderboard·/sharpe·/blog·/pricing·/about·/vacancies·/contact·/links·/terms
⚠Investment research & data tool · not investment advice · not a regulated broker or advisor · past performance does not guarantee future results.